Actively Recruiting
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Led by 3H Pharmaceuticals Co., Ltd. · Updated on 2026-01-21
170
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
CONDITIONS
Official Title
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to sign informed consent and follow study schedule
- Male or female aged 18 years or older at time of consent
- At least one measurable lesion according to RECIST v1.1
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
You will not qualify if you...
- Presence of meningeal diseases or carcinomatous meningitis
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage every two weeks or more often
- Treatment with other investigational drugs within 4 weeks before first dose
- Any unresolved adverse events from prior anti-tumor therapy above Grade 1, except alopecia or certain Grade 2 events deemed safe
- Clinically significant corneal or retinal disease or keratopathy, including conditions like keratoconjunctivitis or corneal abrasion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
S
Shuchao Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here